Kezar Life Sciences, Inc.
NASDAQ: KZR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher J. Kirk
- Employees
- 55
- Headquarters
- South San Francisco, United States
- IPO year
- 2018
- Market cap
- $53.9M
- Website
- https://www.kezarlifesciences.com
Loading KZR…
Loading profile data…Frequently asked questions about KZR
What does Kezar Life Sciences, Inc. (KZR) do?
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specia...
Where does KZR trade?
Kezar Life Sciences, Inc. (KZR) trades on the NASDAQ Global Select.
What sector is KZR in?
Kezar Life Sciences, Inc. (KZR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kezar Life Sciences, Inc.?
Christopher J. Kirk is the chief executive officer of Kezar Life Sciences, Inc. (KZR).
Where is Kezar Life Sciences, Inc. headquartered?
Kezar Life Sciences, Inc. is headquartered in United States.
Does KZR pay a dividend?
Kezar Life Sciences, Inc. (KZR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KZR go public?
Kezar Life Sciences, Inc. (KZR) completed its initial public offering in 2018.